VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Feb. 21, 2007) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that it has initiated a second clinical study to evaluate the efficacy of its near-infrared spectroscopy ("NIRS") device for newly discovered applications related to the diagnosis and characterization of male erectile dysfunction ("ED"). This technology has been developed in collaboration with Dr. Sidney Radomski, MD, Associate Professor of Surgery (Urology) at the University of Toronto. Urodynamix has filed a patent application with the United States Patent and Trademark Office covering ED-related applications of NIRS technology.
